New serological markers in pediatric patients with inflammatory bowel disease

Table 1 Diagnostic value of the new serologic markers in children with inflammatory bowel disease

Marker	Sensitivity		Specificity	PPV	NPV	Ref.
	CD	UC	CD vs UC
Anti-Omp	11%-34%	5%-25%	75%-95%	57.9%-69%	51.6%-53.3%	[8,24,25]
Anti-CBir	52%-56%	ND	ND	ND	ND	[10,13,26]
Anti-I2	44.4%-50%	41.7%-42%	58%-58.3%	51.6%-54.3%	51.1%-53.7%	[27,28]
gASCA	60.7%-62.7%	11.1%-14.6%	85.4%-88.9%	87.1%-92.5%	52.2%-55.9%	[301,31]
ACCA	8.7%-22%	3%-18.5%	81.5%-97%	72.2%-83.3%	32.4%-38.2%	[301,31]
ALCA	19.7%-30.5%	7.6%-14.8%	85.2%-92.4%	81.8%-81.6%	35.9%-40.1%	[301,31]
AMCA	12.2%-16.9%	7.6%-14.8%	85.2%-96.7%	71.4%-86.3%	31.9%-39.06%	[301,31]
Anti-L	18%-22%	3.3%-14.8%	85.2%-96.7%	76.5%-90.3%	33.3%-40.07%	[301,31]
Anti-C	10.2%-22%	2.3%-14.8%	85.2%-97.7%	76.5%-83.3%	33.3%-38.8%	[301,31]
PAB	34%-38.5%	20.4%-20.6%	79.4%-79.6%	62.5%-65.1%	54.7%-56.5%	[44,451]
Anti-GP2	30.2%	8.8%	91.2%	77.4%	56.7%	[45]1
GAB	12.2%	1.9%	98.1%2	86.5%2	52.7%2	[44]

¹Mixed pediatric and adult cohort;

²Ulcerative colitis (UC) vs Crohn’s disease (CD). ND: No data available; Anti-OmpC: Antibodies against outer membrane porin C of Escherichia coli; Anti-CBir1: Antibodies against bacterial flagellin CBir1; Anti-I2: Antibodies against the Pseudomonas-associated sequence; ASCA: Antibodies against Saccharomyces cerevisiae; AMCA: Anti-mannobioside carbohydrate antibodies; ALCA: Anti-laminaribioside carbohydrate antibodies; ACCA: Anti-chitobioside carbohydrate antibodies; Anti-L: Anti-laminarin carbohydrate antibodies; Anti-C: Anti-chitin carbohydrate antibodies; PAB: Pancreatic antibodies; Anti-GP2: Antibodies against glycoprotein 2; GAB: Antibodies against intestinal goblet cells; IBD: Inflammatory bowel disease; PPV: Positive predictive value; NPV: Negative predictive value.